Global Rare Neurological Disease Treatment Market (2020 to 2027) - Analysis and Forecasts

DUBLIN, Aug. 25, 2020 /PRNewswire/ -- The "Rare Neurological Disease Treatment Market to 2027 - Global Analysis and Forecasts by Indication; Drug Type; Distribution Channel; Mode of Administration, and Geography" report has been added to ResearchAndMarkets.com's offering.

The global rare neurological disease treatment market is expected to reach US$13,830.96 million by 2027 from US$ 7,300.12 million in 2019. The market is estimated to grow at a CAGR of 8.5% from 2020 to 2027.

Driving factors of the rare neurological disease treatment market are growing prevalence of rare neurological diseases and favorable pipeline drugs and robust research activities for the treatment of rare neurological diseases. However, high treatment cost incurred is likely to show negative impact on market growth during the forecast period.

Rapid developments in healthcare and drug discovery are leading to the introduction of new therapeutic solutions for the treatment of rare neurological diseases. Authorities such as World Health Organization, National Institute of Neurological Disorders and Stroke, and National Institutes of Health are taking constructive steps to encourage research activities to find a remedy for rare neurological diseases. For instance, in August 2019, National Institute of Neurological Disorders and Stroke and National Center for Advancing Translational Sciences invited researchers to conduct study on rare neurological and neuromuscular diseases.

In order to cope up with rising prevalence of rare neurological diseases and geriatric population, pharmaceutical companies are actively participating in the development of drugs.

For instance, in December 2019, Healx in partnership with Boehringer Ingelheim announced a plan to discover new treatment approaches in the coming years. Additionally, they are planning to discover new therapeutic options for the treatment of fragile X syndrome and Pitt-Hopkins syndrome. Additionally, in January 2020, Ovid Therapeutics, a well-known player in rare neurological diseases treatment market, announced the enrollment of patients for pivotal Phase 3 NEPTUNE trial associated with Angelman syndrome. The results of this research study are expected in mid-2020. Such increasing awareness and developments for rare neurological diseases are likely to boost the growth of the market during the forecast period.

The global rare neurological disease treatment market is segmented into indication, drug type, distribution channel, and mode of administration. The rare neurological disease treatment market, by indication, is further segmented into narcolepsy, amyotrophic lateral sclerosis, Alzheimer's disease, multiple sclerosis, spinal muscular atrophy (SMA), Duchene muscular dystrophy, and other indication. Based on drug type, the rare neurological disease treatment market is further segmented into organic compounds and biologics. Based on distribution channel, the market is further segmented into online pharmacies, hospital pharmacies, and retail pharmacies. The mode of administration segment is classified into oral, injectables.

Reasons to Buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the rare neurological disease treatment market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the global rare neurological disease treatment market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Key Topics Covered:

1. Introduction

2. Rare Neurological Disease Treatment Market - Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Rare Neurological Disease Treatment- Market Landscape
4.1 Overview
4.2 Pest Analysis
4.2.1 North America - PEST Analysis
4.2.2 Europe- PEST Analysis
4.2.3 Asia Pacific- PEST Analysis
4.2.4 Middle East & Africa- PEST Analysis
4.2.5 South and Central America - PEST Analysis

5. Rare Neurological Disease Treatment- Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Rising Prevalence of Rare Neurological Diseases
5.1.2 Favourable Pipeline Drugs and Robust Research Activities for the Treatment of Rare Neurological Diseases
5.2 Key Market Restraints
5.2.1 High Treatment Cost for Rare Neurological Diseases
5.3 Key Market Opportunities
5.3.1 Increasing Awareness of Rare Neurological Diseases Coupled with Developing Healthcare Infrastructure
5.4 Future Trends
5.4.1 Artificial Intelligence for the Treatment of Rare Neurological Diseases
5.5 Impact Analysis

6. Rare Neurological Disease Treatment Market- Global Analysis
6.1 Global Rare Neurological Disease Treatment Market Revenue Forecast And Analysis
6.2 Global Rare Neurological Disease Treatment Market, By Geography - Forecast And Analysis
6.3 Market Positioning of Key Players

7. Rare Neurological Disease Treatment Market Analysis - By Indication
7.1 Overview
7.2 Rare Neurological Disease Treatment Market Share, by Indication, 2019 and 2027 (%)
7.3 Narcolepsy
7.3.1 Overview
7.3.2 Narcolepsy: Rare Neurological Disease Treatment Market- Revenue and Forecast to 2027 (US$ Million)
7.4 Amyotrophic Lateral Sclerosis
7.4.1 Overview
7.4.2 Amyotrophic Lateral Sclerosis: Rare Neurological Disease Treatment Market- Revenue and Forecast to 2027 (US$ Million)
7.5 Alzheimer's Disease
7.5.1 Overview
7.5.2 Alzheimer's Disease: Rare Neurological Disease Treatment Market- Revenue and Forecast to 2027 (US$ Million)
7.6 Multiple Sclerosis
7.6.1 Overview
7.6.2 Multiple Sclerosis: Rare Neurological Disease Treatment Market- Revenue and Forecast to 2027 (US$ Million)
7.7 Spinal Muscular Atrophy (SMA)
7.7.1 Overview
7.7.2 Spinal Muscular Atrophy (SMA): Rare Neurological Disease Treatment Market - Revenue and Forecast to 2027 (US$ Million)
7.8 Duchenne Muscular Dystrophy
7.8.1 Overview
7.8.2 Duchenne Muscular Dystrophy: Rare Neurological Disease Treatment Market - Revenue and Forecast to 2027 (US$ Million)
7.9 Other Indications
7.9.1 Overview
7.9.2 Other Indications: Rare Neurological Disease Treatment Market - Revenue and Forecast to 2027 (US$ Million)

8. Rare Neurological Disease Treatment Market Analysis - By Drug Type
8.1 Overview
8.2 Rare Neurological Disease Treatment Market Share, by Drug Type, 2019 and 2027, (%)
8.3 Organic Compounds
8.3.1 Overview
8.3.2 Organic Compounds: Rare Neurological Disease Treatment Market - Revenue and Forecast to 2027 (US$ Million)
8.4 Biologics
8.4.1 Overview
8.4.2 Biologics: Rare Neurological Disease Treatment Market - Revenue and Forecast to 2027 (US$ Million)

9. Rare Neurological Disease Treatment Market Analysis - By Distribution Channel
9.1 Overview
9.2 Rare Neurological Disease Treatment Market Share, by Distribution Channel, 2019 and 2027, (%)
9.3 Online Pharmacies
9.3.1 Overview
9.3.2 Online Pharmacies: Rare Neurological Disease Treatment Market - Revenue and Forecast to 2027 (US$ Million)
9.4 Hospital Pharmacies
9.4.1 Overview
9.4.2 Hospital Pharmacies: Rare Neurological Disease Treatment Market - Revenue and Forecast to 2027 (US$ Million)
9.5 Retail Pharmacies
9.5.1 Overview
9.5.2 Retail Pharmacies: Rare Neurological Disease Treatment Market - Revenue and Forecast to 2027 (US$ Million)

10. Rare Neurological Disease Treatment Market Analysis - By Mode of Administration
10.1 Overview
10.2 Rare Neurological Disease Treatment Market Share, by Mode of Administration, 2019 and 2027 (%)
10.3 Oral
10.3.1 Overview
10.3.2 Oral: Rare Neurological Disease Treatment Market - Revenue and Forecast to 2027 (US$ Million)
10.4 Inject able
10.4.1 Overview
10.4.2 Inject able: Rare Neurological Disease Treatment Market - Revenue and Forecast to 2027 (US$ Million)

11. Rare Neurological Disease Treatment Market - Geographic Analysis
11.1 North America: Rare Neurological Disease Treatment Market
11.2 Europe: Rare Neurological Disease Treatment Market
11.3 Asia Pacific: Rare Neurological Disease Treatment Market
11.4 Middle East & Africa: Rare Neurological Disease Treatment Market
11.5 South and Central America: Rare Neurological Disease Treatment Market

12. Impact Of COVID-19 Pandemic On Global Rare Neurological Diseases Treatment Market
12.1 North America: Impact Assessment of COVID-19 Pandemic
12.2 Europe: Impact assessment of COVID-19 Pandemic
12.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
12.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

13. Rare Neurological Disease Treatment Market -Industry Landscape
13.1 Overview
13.2 Growth Strategies In The Rare Neurological Disease Treatment Market, 2017-2020
13.3 Inorganic Growth Strategies
13.3.1 Overview
13.4 Organic Growth Strategies
13.4.1 Overview

14. Company Profiles
14.1 Allergan Plc.
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Bayer AG
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 GlaxoSmithKline plc.
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Johnson & Johnson Services, Inc.
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Merck & Co., Inc.
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Novartis AG
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Pfizer Inc.
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Sanofi
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Teva Pharmaceutical Industries Ltd
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Takeda Pharmaceutical Company Limited
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments

15. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/89hqim

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets